Medivir Capital Markets Meeting on 23 February 2017

Stockholm, Sweden — Medivir AB (OMX: MVIR ) today announces that a Capital Markets Meeting will be arranged for investors, analysts and journalists, on Thursday 23 February, at 2pm - 4pm CEST, in Stockholm. 

CEO Niklas Prager and the management team will present a summary of the company’s strategy, platforms and projects and finances after the transformation of the company in 2016. After the presentation there will be a break-out session on the presented projects.

Time: Thursday 23 February, at 2pm - 4pm CEST
Venue:
IVAs Conference Center, Grev Turegatan 16, Stockholm
Invitation for: Institutional investors, analysts and media

The event will also be available after the meeting through Medivir’s website; www.medivir.com

Registration for investors, analysts and journalists
To participate, please register at; http://www.financialhearings.com/event/10014 , no later than 20 February .

For further information, please contact:
Ola Burmark, CFO, mobile: +46 725 480 580.

About Medivir
Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.

Tags:

About Us

Medivir is an emerging and profitable research‐based pharmaceutical company with an established marketing and sales organisation in the Nordic region with a broad portfolio of prescription pharmaceuticals.Medivir receives royalties from Johnson & Johnson on the global sales of the hepatitis C pharmaceutical, Olysio®. In addition, revenues for sales of Olysio in the Nordic region are generated through the company’s own sales and marketing organisation. Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science. The company’s research and development focus is within infectious diseases and oncology and the on-going clinical projects in osteoarthritis and neuropathic pain. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Subscribe

Documents & Links